MSLN and squamous cell carcinoma: Mesothelin is a promising target for CAR T cell therapy (16–18), because up to 30% of cancers are detected with high levels of mesothelin expression, such as epithelial mesothelioma, pancreatic cancer, ovarian cancer, squamous cell carcinomas, adenocarcinomas and triple negative breast cancer (19–21).